🔍

PAUSHAKLTD - Paushak

📊 NSE: PAUSHAKLTD 🏢 Specialty Chemicals 📅 Last Updated: 11/13/2025 15:25

📢 Recent Corporate Announcements

Paushak Ltd Appoints Jain Parkash as Whole-time Director; COO Chintan Gosaliya Resigns

🟡 NEUTRAL ⭐ 6/10

MANAGEMENT 📅 10 Mar 2026, 05:06 PM

Paushak Limited has announced a leadership transition effective from the end of the 2025-26 fiscal year. Mr. Chintan Gosaliya will resign as Whole-time Director and COO on March 31, 2026, to pursue outside opportunities. To ensure continuity, the board has appointed Mr. Jain Parkash, the current Sr. VP of Operational Excellence, as a Whole-time Director for a three-year term starting April 1, 2026. Mr. Parkash brings over 30 years of specialized experience in specialty chemicals and pharma APIs to the role.

Mr. Chintan Gosaliya to step down as Whole-time Director and COO on March 31, 2026.
Mr. Jain Parkash appointed as Whole-time Director for a 3-year term effective April 1, 2026.
New appointee Mr. Parkash has 30+ years of experience in Specialty Chemicals and Agro-Chemicals.
The appointment is an internal promotion and remains subject to shareholder approval via Special Resolution.

💡 Investors should monitor the transition for any shifts in operational strategy, though the internal promotion of an experienced executive suggests a focus on continuity.

Paushak Ltd Appoints Jain Parkash as Whole-time Director; Chintan Gosaliya Resigns as COO

🟡 NEUTRAL ⭐ 6/10

MANAGEMENT 📅 10 Mar 2026, 05:04 PM

Paushak Limited has announced a leadership transition where Mr. Chintan Gosaliya will resign as Whole-time Director and COO effective March 31, 2026. To fill the vacancy, the Board has approved the appointment of Mr. Jain Parkash as an Additional and Whole-time Director for a three-year term starting April 1, 2026. Mr. Parkash is currently the Sr. Vice President of Operational Excellence and brings over 30 years of experience in Specialty Chemicals and Pharma API. This internal promotion suggests a focus on operational continuity and leveraging deep industry expertise.

Mr. Chintan Gosaliya to step down as WTD and COO on March 31, 2026, to pursue outside opportunities.
Mr. Jain Parkash appointed as Whole-time Director for a 3-year term effective April 1, 2026.
Incoming director Mr. Jain Parkash has over 30 years of experience in Specialty Chemicals, Agro-Chemicals, and Pharma API.
The appointment is subject to shareholder approval through a Special Resolution.
Mr. Parkash also serves as a Non-Executive Director on the Board of Alembic Limited.

💡 Investors should monitor the transition for any impact on operational efficiency, though the internal promotion of an experienced industry veteran is generally a stabilizing signal. No immediate action is required as the transition is scheduled for 2026.

Paushak Ltd Appoints Jain Parkash as Whole-time Director; Chintan Gosaliya Resigns as COO

🟡 NEUTRAL ⭐ 6/10

MANAGEMENT 📅 10 Mar 2026, 05:01 PM

Paushak Limited has announced a leadership transition where Mr. Chintan Gosaliya will resign as Whole-time Director and COO effective March 31, 2026. To ensure continuity, the board has appointed Mr. Jain Parkash, currently the Sr. VP of Operational Excellence, as a Whole-time Director for a three-year term starting April 1, 2026. Mr. Parkash brings over 30 years of extensive experience in Specialty Chemicals and Pharma APIs, which are critical sectors for the company. This internal promotion indicates a focus on maintaining operational stability and leveraging internal expertise for future growth.

Mr. Chintan Gosaliya to resign as Whole-time Director and COO effective March 31, 2026.
Mr. Jain Parkash appointed as Whole-time Director for a 3-year term starting April 1, 2026.
New appointee Mr. Parkash has over 30 years of experience in Specialty Chemicals, Agro-Chemicals, and Pharma APIs.
The appointment is subject to shareholder approval through a Special Resolution.
Mr. Parkash also serves as a Non-Executive Director on the Board of Alembic Limited.

💡 Investors should view this as a routine leadership transition; the internal promotion of an industry veteran suggests stability in operational management. No immediate action is required, but shareholders should look for the upcoming Special Resolution to formalize the appointment.

Paushak Ltd Q3 FY26 PAT Drops 59% YoY to ₹6.17 Cr; Revenue Declines to ₹48.8 Cr

🔴 NEGATIVE ⭐ 8/10

EARNINGS 📅 27 Jan 2026, 08:11 PM

Paushak Limited reported a weak performance for the quarter ended December 31, 2025, with Net Profit (PAT) falling 59.5% YoY to ₹6.17 crore from ₹15.26 crore. Revenue from operations saw a marginal decline YoY to ₹48.80 crore but a significant 17% drop on a sequential (QoQ) basis. Profitability was severely impacted by a sharp reduction in Other Income, which fell from ₹6.31 crore to just ₹0.97 crore YoY. Additionally, the company made a provision of ₹1.01 crore towards new Labour Code implementations.

Revenue from Operations stood at ₹48.80 crore, down from ₹58.78 crore in the previous quarter (QoQ).
Net Profit (PAT) declined sharply to ₹6.17 crore compared to ₹15.26 crore in Q3 FY25.
Other Income dropped significantly to ₹0.97 crore from ₹6.31 crore in the corresponding quarter last year.
Restated EPS for the quarter fell to ₹2.50 from ₹6.19 YoY, accounting for the 3:1 bonus issue and stock split.
The company's equity shares were successfully listed on the National Stock Exchange (NSE) effective December 1, 2025.

💡 Investors should exercise caution as the company faces both sequential and year-on-year declines in top-line and bottom-line performance. The significant drop in other income and the impact of new labour provisions warrant a closer look at the core operating margins in upcoming quarters.

Paushak Q3 PAT Drops 60% YoY to ₹6.17 Cr; Revenue Declines 17% QoQ

🔴 NEGATIVE ⭐ 8/10

EARNINGS 📅 27 Jan 2026, 05:29 PM

Paushak Limited reported a significant 59.6% YoY decline in Net Profit to ₹6.17 crore for Q3 FY26, down from ₹15.26 crore. Revenue from operations also faced pressure, falling 17% sequentially to ₹48.8 crore compared to the previous quarter. The company's margins were squeezed by rising employee costs, including a one-time provision of ₹1.01 crore for new labour codes. During the quarter, the company completed a 3:1 bonus issue and stock split, and successfully listed its shares on the NSE.

Net Profit (PAT) plummeted 59.6% YoY to ₹6.17 crore from ₹15.26 crore in the previous year.
Revenue from operations stood at ₹48.8 crore, a 17% decline from ₹58.78 crore in Q2 FY26.
Employee benefit expenses increased to ₹10.90 crore, including a ₹1.01 crore provision for new Labour Codes.
Restated EPS for the quarter fell to ₹2.50 compared to ₹6.19 in the same period last year.
The company successfully listed on the National Stock Exchange (NSE) on December 1, 2025.

💡 The sharp decline in profitability and sequential revenue drop are concerning; investors should wait for signs of margin recovery before increasing exposure. While the NSE listing improves liquidity, the underlying fundamental performance remains under pressure.

Paushak Ltd Commences Phased Production at New Rs 175 Cr Multi-Purpose Plant

🟢 POSITIVE ⭐ 8/10

EXPANSION 📅 21 Jan 2026, 03:15 PM

Paushak Limited has initiated the phased commissioning of its new Multi-Purpose Plant for chemical derivatives and associated infrastructure. The project involves a significant investment of approximately Rs 175 crore, which is being funded through a combination of internal accruals and borrowings. This expansion is strategically designed to replace legacy manufacturing facilities and provide much-needed capacity enhancement, as existing facilities are currently optimally utilized. The full capacity from this expansion is expected to be added progressively over the next 12 months.

Investment of approximately Rs 175 crore in a new Multi-Purpose Plant for derivatives
Commissioning process started in a phased manner to ensure smooth operational transition
Project rationale includes both replacement of legacy facilities and significant capacity enhancement
Proposed capacity to be fully integrated and added over the next 12 months
Financing structured through a mix of internal accruals and external borrowings

💡 Investors should view this as a significant growth catalyst that addresses current capacity constraints. Monitor the quarterly revenue trajectory over the next year to track the successful ramp-up of this new facility.

Paushak Limited CRISIL Rating Reaffirmed; Bank Facilities Enhanced to Rs 145 Crore

🟢 POSITIVE ⭐ 6/10

ROUTINE 📅 15 Jan 2026, 03:18 PM

CRISIL Ratings has reaffirmed Paushak Limited's long-term credit rating at 'CRISIL A/Stable' and assigned a short-term rating of 'CRISIL A1'. The total rated bank loan facilities have been significantly increased from Rs 40 crore to Rs 145 crore. This enhancement includes a new term loan of Rs 70 crore and expanded working capital facilities totaling Rs 75 crore. The reaffirmation of the 'Stable' outlook indicates the company's maintained creditworthiness despite the higher debt capacity.

Long-term credit rating reaffirmed at 'CRISIL A/Stable' by CRISIL Ratings.
Short-term credit rating of 'CRISIL A1' assigned for working capital facilities.
Total bank loan facilities rated increased from Rs 40 crore to Rs 145 crore.
New facilities include a Rs 70 crore Term Loan and Rs 75 crore in total Working Capital limits.
The rating assignment covers both existing and proposed enhanced credit limits.

💡 The reaffirmation of a strong credit rating alongside a significant increase in borrowing limits suggests the company is well-positioned for expansion. Investors should monitor the deployment of the new Rs 70 crore term loan for capital expenditure or growth initiatives.

Paushak Limited Submits Q3 FY26 Compliance Certificate Under SEBI Regulation 74(5)

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 05 Jan 2026, 06:51 PM

Paushak Limited has filed its quarterly compliance certificate for the period ending December 31, 2025, as required under SEBI (Depositories and Participants) Regulations. The certificate, issued by MUFG Intime India Private Limited, confirms that all dematerialization requests were processed and security certificates were mutilated or cancelled within the prescribed timelines. This filing is a standard regulatory requirement to ensure the integrity of the company's shareholding records. It indicates that the company's administrative and registrar processes are functioning as per SEBI mandates.

Compliance certificate submitted for the quarter ended December 31, 2025.
Issued by Registrar and Share Transfer Agent (RTA) MUFG Intime India Private Limited.
Confirms dematerialization requests were processed and confirmed to depositories within timelines.
Ensures security certificates were mutilated and cancelled after verification by the depository participant.

💡 This is a routine administrative filing with no impact on company fundamentals. No action is required from investors.

Paushak Limited to Close Trading Window from January 1, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 26 Dec 2025, 02:46 PM

Paushak Limited has announced the closure of its trading window for all designated persons and their immediate relatives starting January 1, 2026. This move is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the upcoming financial results. The closure pertains to the unaudited financial results for the quarter and nine-month period ending December 31, 2025. The trading window will reopen 48 hours after the results are officially declared to the exchanges.

Trading window closure effective from January 1, 2026
Closure relates to financial results for the period ending December 31, 2025
Window to remain closed until 48 hours post-result declaration
Board meeting date for results approval to be announced in due course

💡 This is a routine regulatory announcement with no impact on company fundamentals; investors should monitor for the upcoming board meeting date to review quarterly performance.

View All PAUSHAKLTD Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Overall revenue declined by 2.8% from INR 212 Cr in FY23 to INR 206 Cr in FY24 due to pricing corrections and macroeconomic headwinds. However, H1 FY25 revenue grew 7.9% YoY to INR 109 Cr from INR 101 Cr, driven by a recovery in demand for phosgene-based intermediates.

Geographic Revenue Split

Domestic sales dominate the profile, while foreign exchange earnings for FY25 were INR 21.78 Cr, contributing approximately 10% to the total income, reflecting a global footprint in specialty chemical solutions.

Profitability Margins

PAT margins improved from 25.4% in FY23 to 26.2% in FY24 despite lower revenue. Operating margins moderated from 35% in FY23 to 31% in FY24 and further to 25.4% in early FY24 due to a shift toward high-volume semi-specialized products with lower margins.

EBITDA Margin

Operating EBITDA margins stood at 31% in FY24, a decrease from 35% in FY23. This 400 bps compression resulted from pricing pressure caused by the resurgence of Chinese manufacturers and customer destocking in the agrochemical and pharma sectors.

Capital Expenditure

The company is undertaking a significant capital expenditure of INR 240 Cr over FY25 and FY26 to expand downstream capacities and diversify into semi-specialized products, compared to a more modest INR 50-60 Cr spent in previous cycles.

Credit Rating & Borrowing

CRISIL reaffirmed a 'CRISIL A/Stable' rating. The company maintains a debt-free status (Adjusted debt/networth of 0) with an exceptional interest coverage ratio of 528.41 times in FY24.

⚙️ Operational Drivers

Raw Materials

Phosgene gas (manufactured in-house), Chlorine, and Carbon Monoxide are primary inputs. The company benefits from a low import bill as most raw materials are sourced domestically, insulating it from global supply chain volatility.

Import Sources

Primarily sourced from India (Gujarat region) to leverage the local chemical ecosystem. Foreign exchange outgo was minimal at INR 0.98 Cr in FY25, indicating high domestic procurement.

Key Suppliers

Not specifically named, but the company relies on domestic industrial gas and chemical suppliers for chlorine and carbon precursors.

Capacity Expansion

Current downstream capacities are running at optimal/high utilization. The planned INR 240 Cr expansion over FY25-26 aims to increase throughput and enable the production of semi-specialized products to capture higher market volume.

Raw Material Costs

Raw material costs are susceptible to pricing fluctuations in the specialty chemicals industry. Backward integration into phosgene gas manufacturing provides a cost advantage and supports robust margins of 25-31%.

Manufacturing Efficiency

Efficiency is driven by automated operations in new facilities, which have improved process safety, quality consistency, and throughput.

Logistics & Distribution

Not disclosed as a specific percentage, but the company caters to global customers, implying a robust logistics network for hazardous chemical transport.

📈 Strategic Growth

Expected Growth Rate

Growth Strategy

Growth will be achieved through an INR 240 Cr investment in downstream capacities and a strategic shift toward semi-specialized products. The company is leveraging the 'China Plus One' strategy to become a dependable global partner for phosgene-based intermediates.

Products & Services

Phosgene-based specialty chemicals including Chloroformates, Isocyanates, Carbonates, and Phosgene gas sold to pharmaceutical and agrochemical industries.

Brand Portfolio

Operates under the corporate brand 'Paushak' and is part of the established 'Alembic' group.

New Products/Services

Expansion into semi-specialized products is expected to drive volume growth, although these products typically carry lower margins than pure specialty intermediates.

Market Expansion

Targeting global supply chain diversification by positioning as a 'China Plus One' alternative for multinational pharmaceutical and agrochemical companies.

Market Share & Ranking

One of the few players in India licensed to manufacture phosgene gas, creating a significant regulatory moat and a leading position in this niche segment.

Strategic Alliances

Benefits from strong parentage and financial support from Nirayu Limited (holding 53% stake), which has a market value of holdings exceeding INR 15,200 Cr.

🌍 External Factors

Industry Trends

The specialty chemicals industry is evolving toward sustainable and seamless solutions. Paushak is positioning itself to benefit from the 'China Plus One' trend by modernizing facilities and increasing operational efficiency.

Competitive Landscape

Competes with global and domestic specialty chemical players, with competition intensifying from Chinese manufacturers post-lockdown.

Competitive Moat

The primary moat is the government license for phosgene gas manufacturing, which is highly restricted. This regulatory barrier, combined with backward integration, is highly sustainable and prevents new entrants.

Macro Economic Sensitivity

Sensitive to global GDP (3.2% growth) and Indian manufacturing sector growth (6.3% GDP growth), which drives demand for end-user pharmaceutical and agrochemical products.

Consumer Behavior

Shift toward dependable and sustainable supply chain partners among global pharmaceutical companies favors Paushak's long-term engagement strategy.

Geopolitical Risks

Resurgence of Chinese manufacturing and global trade shifts are primary risks that influence domestic pricing and demand sentiments.

⚖️ Regulatory & Governance

Industry Regulations

Operations are strictly governed by the Chemical Weapon Convention Act, 2000 and the Disaster Management Act, 2005 due to the hazardous nature of phosgene gas.

Environmental Compliance

Compliant with The Environment (Protection) Act, 1986 and The Chemical Accident (Emergency) Planning Preparedness & Response Rules, 1998. CSR spend was INR 1.06 Cr in FY25.

Taxation Policy Impact

Effective tax rate is consistent with Indian corporate standards; PAT of INR 54 Cr on healthy margins suggests stable fiscal management.

Legal Contingencies

Secretarial audit reports compliance with applicable acts; no major pending litigation or material court cases with specific INR values were disclosed.

⚠️ Risk Analysis

Key Uncertainties

Fluctuations in input prices and demand sentiments in the agrochemical sector could impact operating profitability by over 5% if margins fall below the 20% threshold.

Geographic Concentration Risk

Manufacturing is concentrated in Vadodara, Gujarat, making it sensitive to regional industrial policies and environmental regulations.

Third Party Dependencies

Low dependency on third-party raw material suppliers due to high backward integration, but dependent on the parent company Nirayu for potential financial support for large capex.